FDA Rejects Self-Injected Version of AstraZeneca’s Lupus Drug
The US Food and Drug Administration rejected a subcutaneous version of AstraZeneca Plc’s lupus medicine that would make it easier to administer.
By Ashleigh Furlong · Bloomberg Markets
The US Food and Drug Administration rejected a subcutaneous version of AstraZeneca Plc’s lupus medicine that would make it easier to administer.